Namilumab or infliximab compared with standard of care in hospitalised patients with COVID-19 (CATALYST): a randomised, multicentre, multi-arm, multistage, open-label, adaptive, phase 2, proof-of-concept trial
- Resource Type
- Article
- Source
- The Lancet Respiratory Medicine; 20240101, Issue: Preprints
- Subject
- Language
- ISSN
- 22132600; 22132619